Insmed reports fourth-quarter and full-year 2024 financial results and provides business update

—arikayce® (amikacin liposome inhalation suspension) total revenue of $104.4 million for fourth-quarter and $363.7 million for full-year 2024, reflecting 19% annual growth and exceeding the upper end of full-year 2024 guidance range— —company reiterates 2025 global arikayce revenue guidance of $405 million to $425 million, reflecting double-digit growth compared to 2024— —nda for brensocatib in patients with bronchiectasis accepted by fda and granted priority review with a pdufa target action date of august 12, 2025— —phase 2b study of tpip in patients with pah, phase 2b birch study of brensocatib in patients with crssnp, and phase 3 encore study of arikayce remain on track for topline data in mid-2025, end of 2025, and first quarter of 2026, respectively— —company ends 2024 with approximately $1.4 billion of cash, cash equivalents, and marketable securities— bridgewater, n.j. , feb. 20, 2025 /prnewswire/ -- insmed incorporated (nasdaq: insm), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the fourth quarter and full year ended december 31, 2024 and provided a business update.
INSM Ratings Summary
INSM Quant Ranking